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Abstract
Background: The potential of neuroprotective agents should be revisited in the era of endovascular thrombectomy
(EVT) for acute large-artery occlusion because their preclinical effects have been optimized for ischemia and reperfusion
injury. Neu2000, a derivative of sulfasalazine, is a multi-target neuroprotectant. It selectively blocks N-methyl-D-aspartate
receptors and scavenges for free radicals. This trial aimed to determine whether neuroprotectant administration before
EVT is safe and leads to a more favorable outcome.
Methods: This trial is a phase-II, multicenter, three-arm, randomized, double-blinded, placebo-controlled, blinded-
endpoint drug trial that enrolled participants aged ≥ 19 years undergoing an EVT attempt less than 8 h from symptom
onset, with baseline National Institutes of Health Stroke Scale (NIHSS) score≥ 8, Alberta Stroke Program Early CT score≥ 6,
evidence of large-artery occlusion, and at least moderate collaterals on computed tomography angiography.
EVT-attempted patients are randomized into control, low-dose (2.75 g), and high-dose (5.25 g) Neu2000KWL
over 5 days. Seventy participants per group are enrolled for 90% power, assuming that the treatment group
has a 28.4% higher proportion of participants with functional independence than the placebo group. The primary
outcome, based on intention-to-treat criteria is the improvement of modified Rankin Scale (mRS) scores at 3 months
using a dichotomized model. Safety outcomes include symptomatic intracranial hemorrhage within 5 days. Secondary
outcomes are distributional change of mRS, mean differences in NIHSS score, proportion of NIHSS score 0–2, and
Barthel Index > 90 at 1 and 4 weeks, and 3 months.
Discussion: The trial results may provide information on new therapeutic options as multi-target neuroprotection might
mitigate reperfusion injury in patients with acute ischemic stroke before EVT.
Trial registration: ClinicalTrials.gov, ID: NCT02831088. Registered on 13 July 2016.
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Background
Recent clinical trials of endovascular thrombectomy
(EVT) have shown a remarkably positive effect on the
functional outcome of patients with acute ischemic
stroke presenting with proximal anterior circulation oc-
clusion [1]. However, a considerable number of individ-
uals with stroke still remain disabled despite a higher
rate of reperfusion and a striking improvement in clin-
ical outcome by the recent use of stent retrievers [2].
Numerous endeavors have been devoted to attenuating
neuronal cell death after ischemic injury, and “excito-
toxicity” is considered one of the therapeutic targets for
neuroprotection in acute ischemic stroke [3]. Herein,
N-methyl-D-aspartate (NMDA) receptors play a role in
excitatory neurotransmission, and their overactivation
results in neuronal death after acute ischemic stroke.
NMDA-receptor antagonists prevent such excitatory ac-
tion of glutamate and cellular calcium overload. Unfor-
tunately, no randomized controlled trials have succeeded
in demonstrating the clinical efficacy of such drugs [4].
Potential reasons for the failure are explained by model-
ing mismatch between preclinical experiments and hu-
man stroke, adverse effects of the drugs, inappropriate
time window, or complexity of the ischemic cascade [5].
Such limitations are being resolved with improvements
in therapeutic strategies. First, the potential of neuropro-
tective agents as a promising treatment strategy in
patients with acute ischemic stroke is being revisited in
the EVT era because their preclinical efficacy has been
optimized in ischemia and reperfusion models [6]. In
this regard, neuroprotective actions of drugs may be
optimized when cerebral blood flow is restored in actual
clinical practice for acute ischemic stroke. Second, to
address the complexity of the ischemic cascade, a multi-
target neuroprotective modality, such as therapeutic
hypothermia, is gaining evidence in cardiac arrest [7].
Such multi-step or multi-target treatment would be
highly beneficial after recanalization in patients with
acute ischemic stroke [8].
Neu2000 (a derivative of sulfasalazine) is a novel,
multi-target neuroprotectant that combines modest (mi-
cromolar) NR2B subtype-selective blockade of NMDA
receptors with potent (nanomolar) scavenging of reactive
oxygen species [9, 10] (Fig. 1). It has been suggested that
the prior failure of more potent, and subtype-unselective
NMDA-receptor antagonist drugs in stroke trials may
have been partly due to excessive reduction of intracellu-
lar free calcium levels and consequent enhancement of
ischemic neuronal apoptosis [11]. Neu2000 seeks to
blunt acute excitotoxicity without risking this downside,
and then to additionally target downstream free-radical
damage, which is prominently triggered by vascular re-
perfusion. The neuroprotective potential of Neu2000 has
been well demonstrated in preclinical animal stroke
Fig. 1 Simplified illustration of possible mechanisms after Neu2000 administration to mitigate reperfusion injury in the setting of recanalization
treatment. a Ischemic cascade after stroke and proposed effect of multi-target neuroprotection. b The expected effect of reperfusion with multi-
target neuroprotection on burden of cell damage and functional outcome
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models with a favorable efficacy and a wide range of
therapeutic window profile [9, 10, 12, 13]. In human
phase-I studies, there are no serious adverse events
including psychosis [14]. The current trial aims to pro-
vide proof-of-concept for use of Neu2000 as an adjunct
neuroprotective agent together with state-of-the-art




The Safety and Optimal Neuroprotection of neu2000 in
acute Ischemic stroke with reCanalization (SONIC) trial is
a multicenter, national, prospective, randomized, three-arm,
parallel-group, double-blinded, placebo-controlled, phase-II
clinical study with blinded-endpoint evaluation carried out
in the Republic of Korea. This study aims to examine the
effects of neuroprotectants in EVT-attempted patients
within 8 h of stroke onset. All participating centers had
received Institutional Review Board approval prior to trial
initiation. Emergency medical consent is obtained from
caregivers before study enrollment. Approval was obtained
from the Institutional Review Board of each center. The
flowchart of this study is shown in Fig. 2. The Standard
Protocol Items Recommendations for Interventional Trials
(SPIRIT) checklist is attached as Additional file 1.
Patient population
We will enroll acute ischemic stroke patients with mod-
erate to severe neurological deficits (at least National
Institutes of Health Stroke Scale (NIHSS) score ≥ 8) and
imaging confirmation of proximal vessel occlusion in the
anterior circulation. Before randomization, local investi-
gators will assess imaging criteria with the Alberta
Stroke Program Early CT Score (ASPECTS), definite
proximal artery occlusion, and collateral status on base-
line computed tomography (CT) and CT angiography
(Fig. 2). Detailed study inclusion and exclusion criteria
are shown in Table 1.
Randomization
Participants will be randomly assigned in a 1:1:1 fashion
to one of three arms: (1) high-dose, (2) low-dose, or (3)
placebo. Randomization is based on computer-generated
cards before study initiation and will be handed to autho-
rized personnel in a sealed envelope. All study investiga-
tors and participants are masked to treatment allocation
except investigational product (IP)-preparing personnel.
The randomization schedule is not accessible except for
safety reasons, until completion of this trial. Study drugs
and the placebo are provided in an identical package.
Treatment
A study subject is enrolled after clinical judgment with in-
clusion and exclusion criteria on the basis of acute-onset
neurological manifestation, confirmed by imaging for arterial
vessel occlusion. Written informed consent is obtained from
the patient or a legal representative before enrollment. After
Fig. 2 The flowchart of SONIC trial. CT computed tomography, CTA
computed tomography angiography, IV intravenous, tPA tissue
plasminogen activator, ASPECTS Alberta Stroke Program Early CT
Score, IP investigational product, MRI magnetic resonance imaging
Hong et al. Trials  (2018) 19:375 Page 3 of 7
enrollment, the study subject undergoes rapid endovascular
recanalization therapy. The neuro-interventionist uses any
available modality (stent retriever or aspiration thrombec-
tomy) or its combination to achieve safe recanalization. In
addition, the use of a balloon-guided catheter is recom-
mended in the relevant internal carotid artery. All groups
will receive the best current standard of care as described in
the current local guidelines for acute stroke management:
This represents the fact that they will receive tissue plas-
minogen activator intravenously in a 4.5-h window if they
meet the accepted criteria [15].
The assigned groups are injected with intravenous ad-
ministration of IP as a high-dose, low-dose, or placebo
of Neu2000KWL (2-hydroxy-5-(2,3,5,6-tetrafluoro-4-tri-
fluoromethyl-benzylamino)-benzoic acid) before recana-
lization attempt by the personnel who are blinded to
treatment allocation. The first infusion is intended to be
initiated before thrombus retrieval. Subsequent injection
will be administered twice per day (12-h interval) during
five consecutive days. In the high-dose group, the initial
infusion dose is 750 mg mixed with 250 mL of saline;
the subsequent nine doses are 500 mg (total dose:
5250 mg). In the low-dose group, the initial infusion
dose is 500 mg, and the subsequent nine doses are
250 mg (total dose: 2750 mg). The placebo group re-
ceives 250 mL of saline 10 times. The infusion volume is
250 mL in all groups. All patients receive care in the
stroke unit or neuro intensive care unit. Follow-up im-
aging studies will be obtained as computed tomography
(CT) angiography at 24–48 h from the first infusion and
subsequent magnetic resonance imaging within 24 h
from the last infusion. Follow-up images play a role in
the detection of adverse effects of the study drug.
All patients visit at the fourth week and third month after
randomization. During follow-up, modified Rankin Scale
(mRS) score, NIHSS score, and Barthel Index (BI) will be
determined. Adverse events are collected throughout the
study. Detailed follow-up schedules and procedures are
shown in Fig. 3.
Table 1 Study inclusion and exclusion criteria
Inclusion criteria
1. Age ≥ 19 years
2. Subject who is presented to hospitals after onset of brain ischemic
symptoms from the base of last normal state and can start endovascular
therapy in accordance with standard practice guidelines within 8 h after
the symptom onset
3. NIHSS ≥8 at screening time point
4. Subject whose activity is possible without the help of others in the
general condition 1 day before the ischemic stroke onset and prestroke
Barthel Index scores > 90
5. Subject whose cerebral CT and CTA imaging confirm acute ischemic
stroke and symptomatic intracranial occlusion at screening and whose
occlusion site considered the cause of acute ischemic stroke meets the
following conditions: T- or L-type ICA occlusion, MCA M1 occlusion,
MCA-M1 equivalent (2 or more MCA-M2, anterior temporal artery is not
regarded M2)
6. Subject with ASPECTS ≥ 6 on cerebral non-contrast CT
7. Subject who spontaneously submit a written informed consent to
participate in this trial
Clinical exclusion criteria
1. A medical history of hypersensitivity against aspirin (salicylates),
sulfasalazine, or 5-ASA
2. Subject whose heart diseases were confirmed at screening: Subject
who was diagnosed with myocardial infarction within 6 months; subject
who had severe arrhythmia evoking clinical symptoms (respiratory
difficulties, tachycardia, etc.) within 6 months; subject whose ECG
measured at the emergency room confirms the following results: A.
pulse rate < 50 or > 120 beats/min. B. 2nd or 3rd degree AV block. C.
congenital or acquired QT syndrome. D. ventricular pre-excitation
syndrome
3. Subject who was diagnosed with heart failure ≥ New York Heart
Association class II
Class I: patients with no limitation of activities; they suffer no
symptoms from ordinary activities
Class II: patients with slight, mild limitation of activity; they are
comfortable with rest or with mild exertion
Class III: patients with marked limitation of activity; they are
comfortable only at rest
Class IV: patients who should be at complete rest, confined to bed or
chair; any physical activity brings on discomfort and symptoms occur
at rest
4. Subject who has a contraindication to iodinated contrast media
5. Subject who is receiving renal replacement therapy such as dialysis
due to acute or chronic renal failure
6. Subject who is diagnosed with cancer or received cancer therapy
within 6 months or has recurrent or metastatic cancer
7. Subject who shows a high body temperature of 38 °C or more or
who need antibiotic therapy due to infectious diseases
8. Subject who takes pharmacotherapy for liver diseases such as
hepatitis or liver cirrhosis
9. Subject who is pregnant or lactating. In case of women of child-
bearing potential, only subjects who are confirmed as not being preg-
nant can participate in this trial
10. Subject who participated in other clinical studies within the past
3 months. In case of participation in an observational study without
medication, the subject can participate in this trial
11. Subject who was determined inappropriate for participation in this
trial due to other reasons
Imaging exclusion criteria
Table 1 Study inclusion and exclusion criteria (Continued)
1. Baseline CT evidence of intracranial hemorrhage
2. Baseline CT evidence of intracranial tumor on presentation
3. Baseline CTA shows that the site of occlusion considered to be the
cause of acute ischemic stroke meets the following conditions:
A. MCA + PCA or MCA + ACA occlusion in carotid T/L-type
B. Occlusion of a bilateral intracranial large artery
C. Simultaneous involvement of anterior and posterior circulation
4. Absence of the collateral circulation corresponding to one of the
followings: CTA imaging shows absence or minimal collateral circulation
at ≤ 50% of MCA territories, compared with pial filling of the
contralateral side
NIHSS National Institutes of Health Stroke Scale, CT computed tomography,
CTA computed tomography angiography, ICA internal carotid artery, MCA
middle cerebral artery, ASPECTS Alberta Stroke Program Early CT Score, ASA
aminosalicylate, ECG electrocardiography, PCA posterior cerebral artery, ACA
anterior cerebral artery
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Blinding
Treatment assignment will remain blind in both the pa-
tient and treating physician except IP-preparing personnel.
The IP-preparing personnel are not involved in any other
aspect of the study. Study outcomes at baseline, day 7, the
fourth week, and third month will be assessed with
standardized forms and procedures by separate certified
investigators blinded to the treatment. Finally, the
Blinded-endpoint Monitoring Board will determine the
primary endpoint through central adjudication. Results of
neuroimaging will also be assessed by the imaging core
laboratory team who are unaware of the treatment
allocation.
Study outcome
The primary outcome will be assessed by a dichotomous
model: the proportion of patients with mRS 0–2 and
that with mRS 3–6 at 3 months. Safety outcomes are all
serious adverse events and symptomatic intracranial
hemorrhage with neurologic deterioration (NIHSS score
≥ 4) on cerebral CT within 24–48 h after randomization
[16]. The secondary outcomes are as follows: distribu-
tional change of mRS, difference in NIHSS score, ratio
of NIHSS score 0–2, and ratio of BI ≥ 90 at 1, 4 weeks,
and 3 months. All local principal investigators (PI) have a
consensus meeting for imaging interpretation before the
start of the trial and present regular meeting bi-annually.
Imaging endpoints
After completion of patient enrollment, all imaging data
will be evaluated by the core imaging laboratory. Stroke
neurologists, neuroradiologists, and neurointerventionists
with expertise in acute stroke management will perform
core laboratory imaging analyses to ensure consistent
grading and eliminate possible bias after de-identification
and blinding of clinical data. The core laboratory team will
assess the ASPECTS, infarct volume, recanalization de-
fined by modified Thrombolysis in Cerebral Infarction
grades, and the presence of hemorrhagic transformation.
All core laboratory readings will be performed independ-
ently by two experienced readers. Discrepancies will be
resolved by a third, independent reader.
Sample size estimates
The primary hypothesis of this study is that patients re-
ceiving Neu2000 before EVT will have an increased pro-
portion of 3-month functional independence (mRS 0–2),
compared with those receiving placebo. The expected
proportions of functional independence are 41.6% and
70.0% in the placebo and Neu2000 groups, respectively.
Such assumptions are based on the results of CT-based
EVT trials (MR CLEAN [17] and ESCAPE [18]), and the
preclinical Neu2000 research with transient occlusion
model [9]. We chose the target sample size of 63 partici-
pants per group to provide 90% power, at a two-sided
alpha of 0.05 to prove a treatment effect. The total
Fig. 3 Schedule of enrollment, interventions, and assessments in SONIC trial as per Standard Protocol Items: Recommendations for Interventional
trials (SPIRIT)
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sample size was determined to be 210 considering a 10%
dropout rate for the primary endpoint.
Statistical analyses
The primary outcome analysis is based on the intention-
to-treat principle. Statistical testing for the primary end-
point is conducted using the chi-square test for the
comparison of functional independence among the three
arms at a two-sided significance threshold of 10%. In
case of significant differences, comparisons between the
placebo and low-dose Neu2000 groups, and placebo and
high-dose Neu2000 groups will be conducted. For sec-
ondary outcome analyses, the Cochran-Mantel-Haenszel
test, the two-way analysis of variance test, and the
chi-square test will be performed on the per-protocol
population. In addition, multivariate analysis will be used
to adjust for potential confounders, such as age, stroke
severity, time to EVT onset, previous stroke, atrial fibril-
lation, diabetes mellitus, ASPECTS, and T-type internal
carotid artery occlusion. If there are missing data despite
best efforts to keep all missing data to a minimum, then
missing outcome data will be not substituted for the pri-
mary outcome analysis.
Study organization and data monitoring body
The Steering Committee consists of local principal investi-
gators, stroke neurologists, neuroradiologists, and neu-
rointerventionists from each center, members of the
Advisory Committee, and independent trial statisticians.
The Trial Executive Committee consists of six principal
investigators. Subcommittees exist for blinded-endpoint
assessment, adverse event adjudication, and imaging ana-
lysis. All data will be entered into a web-based trial man-
agement system by trained local research nurses. The trial
coordinator at the central trial office will carefully review
and fully check all local data against source data.
Discussion
The SONIC trial intends to show that Neu2000 before
EVT can be safely administered and have a positive effect
on tissue damage and clinical outcomes. Despite recent ad-
vances in EVT, considerable functional dependence (14–
58%) still remains in patients with successful recanalization
(60–90%) [2]. Ameliorating reperfusion injury is a possible
target for new drug development; new drug trials are on-
going with uric acid, therapeutic hypothermia, and various
neuroprotectants in EVT-attempted patients with stroke
[3]. In addition, imaging findings according to the assigned
groups will be informative in an effort to ameliorate
reperfusion injury including edema and hemorrhagic
transformation.
Our trial also intends to show that Neu2000 before EVT
can be safely administered and have a positive effect on
tissue damage and clinical outcomes in patients with acute
ischemic stroke. This proof-of-concept trial will also show
whether it would be more effective in specific clinical
targets. In addition, this trial will investigate whether the
escalating dose mitigates the ischemic damages shown in
preclinical experiments [9]. Single-target neuroprotectants
have failed in acute stroke clinical trials despite remarkable
success in preclinical studies [19]. Multi-target neuropro-
tective strategy using Neu2000 is challengeable in its activ-
ity on timely blocking the sequential ischemic cascade,
which is responsible for eventual neuroglial death after is-
chemic stroke (Fig. 1).
This trial is a novel study focusing on adjuvant neuro-
vascular protection against ischemia-reperfusion injury in
humans by selecting eligible patients as described above.
Neu2000 is a first-in-class multi-target drug inhibiting
NMDA-receptor-induced excitotoxicity, free-radical tox-
icity, and blood-brain barrier disruption. Future phase-III
trials with solid evidence, like shift analysis, should be
considered for establishing the neuroprotective properties
in acute ischemic stroke.
Trial status
This report describes the protocol, version 4.0, 19 June
2017. SONIC is currently recruiting study participants.
The first patient was randomized in September 2016, and
the targeted end date for recruitment is December 2018.
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